tetano
Editor, Senior Moderator
Int J Antimicrob Agents
. 2020 Jun 2;106043.
doi: 10.1016/j.ijantimicag.2020.106043. Online ahead of print.
Tocilizumab Administration in a Refractory Case of COVID-19
Farzaneh Dastan[SUP] 1 [/SUP], Seyed Alireza Nadji[SUP] 2 [/SUP], Ali Saffaei[SUP] 3 [/SUP], Payam Tabarsi[SUP] 4 [/SUP]
Affiliations
Abstract
Novel coronavirus (COVID-19) pneumonia as a pandemic disease leads to acute respiratory distress syndrome (ARDS), acute cardiac injury, multi organ failure, and shock. In the absence of specific treatment for COVID-19, there is an urgent need to find the alternative treatments to manage this pandemic. Pathophysiological studies have demonstrated the role of inflammatory mediators in COVID-19 pneumonia. It appears that imbalances between inflammatory and anti-inflammatory cytokines are the probable underlying mechanism. Since, there is no specific treatment for the inflammatory phase of COVID-19 pneumonia, consideration of treatments, such as tocilizumab, as salvage therapy is necessary. Here, we reported a challenging case of COVID-19 who was successfully treated with tocilizumab.
Keywords: Acute respiratory distress Syndrome; COVID-19; Coronavirus; Interleukin-6, Tocilizumab.
. 2020 Jun 2;106043.
doi: 10.1016/j.ijantimicag.2020.106043. Online ahead of print.
Tocilizumab Administration in a Refractory Case of COVID-19
Farzaneh Dastan[SUP] 1 [/SUP], Seyed Alireza Nadji[SUP] 2 [/SUP], Ali Saffaei[SUP] 3 [/SUP], Payam Tabarsi[SUP] 4 [/SUP]
Affiliations
- PMID: 32502524
- PMCID: PMC7264941
- DOI: 10.1016/j.ijantimicag.2020.106043
Abstract
Novel coronavirus (COVID-19) pneumonia as a pandemic disease leads to acute respiratory distress syndrome (ARDS), acute cardiac injury, multi organ failure, and shock. In the absence of specific treatment for COVID-19, there is an urgent need to find the alternative treatments to manage this pandemic. Pathophysiological studies have demonstrated the role of inflammatory mediators in COVID-19 pneumonia. It appears that imbalances between inflammatory and anti-inflammatory cytokines are the probable underlying mechanism. Since, there is no specific treatment for the inflammatory phase of COVID-19 pneumonia, consideration of treatments, such as tocilizumab, as salvage therapy is necessary. Here, we reported a challenging case of COVID-19 who was successfully treated with tocilizumab.
Keywords: Acute respiratory distress Syndrome; COVID-19; Coronavirus; Interleukin-6, Tocilizumab.